NovoCure(NASDAQ) NVCR

NovoCure makes wearable devices that use electric fields to treat cancer. These tools help patients fighting aggressive tumors like brain and lung cancer. The therapy works alongside other treatments to slow or stop cancer growth.

Fighting Cancer with Electric Fields

• Optune Gio: Medical device using electric fields to treat adults with newly diagnosed or recurring glioblastoma, a type of brain cancer.
• Optune Lua: Therapy used to treat metastatic non-small cell lung cancer and malignant pleural mesothelioma, a cancer of the chest lining.
• Optune Pax: Portable device approved in February 2026 for treating locally advanced pancreatic cancer in combination with specific chemotherapies.
• TTFields Platform: Proprietary technology that delivers physical forces through skin-contact arrays to disrupt cancer cell division.

Recent Milestones and Market Growth

• Secured FDA approval for Optune Pax in February 2026 for the treatment of pancreatic cancer.
• Submitted a Premarket Approval application to the FDA in December 2025 for Optune Mya to treat brain metastases.
• Partnered with Zai Lab to commercialize products and expand clinical trials across Greater China.
• Announced a national reimbursement policy in Japan for Optune Lua in March 2026 to increase patient access.

Scaling a Global Therapy Network

NovoCure maintains a global footprint with commercial operations in the United States, Germany, France, and Japan. The company holds hundreds of issued patents worldwide to protect its proprietary electric field therapy platform.

Tracking the Performance Trajectory

• Net revenue reached $174.1 million in Q1 2026, a 12.3% increase compared to Q1 2025.
• Gross profit was $135.1 million in Q1 2026, up 16% from the previous year.
• Net loss deepened to $71.1 million in Q1 2026, compared to a loss of $34.3 million in Q1 2025.
• Operating cash flow improved to a loss of $13.5 million in Q1 2026, up from a $35.7 million loss in Q1 2025.
• Cash and short-term investments totaled $432 million as of March 31, 2026.

Bottom Line

NovoCure has transitioned from a single-product company to a multi-indication oncology platform. Its ongoing clinical trials and recent regulatory approvals support its expansion into new cancer types.